Drugs Made In America Acquisition II Corp. Ordinary Shares
DMII - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$649.1M
Close$
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $649.10 Million |
|---|---|
| Enterprise Value | $649.38 Million |
| Earnings per Share | $0.07 |
| Beta | 0.04 |
| Outstanding Shares | 50,000,000 |
Return
| Return on Equity | 2.62% |
|---|---|
| Return on Assets | 2.53% |
| Return on Invested Capital | -0.28% |
Valuation & Multiples
| P/E Ratio | 0.39 |
|---|---|
| PEG | 0 |
| Price to Sales | - |
| Price to Book Ratio | 1.13 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -448.67 |
| Enterprise Value to Net Income | 49 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Institutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 90.96%▲ 3.10% |
|---|---|
| Total Invested | $457.57M▲ 4.44% |
| Investors Holding | 70▲ 2.00% |
About Drugs Made In America Acquisition II Corp. Ordinary Shares
2 employees
CEO: Roger Bendelac
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a rec...